Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
Zsolt Mezei,1 Daniel Bereczki,1,2 Lilla Racz,1 Laszlo Csiba,1 Tunde Csepany11Department of Neurology, University of Debrecen, Debrecen, Hungary; 2Department of Neurology, Semmelweis University, Budapest, HungaryBackground: Decreased relapse rate and slower disease progression have been reported with...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c27bafa17a504a3095bcb3740933dfa2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c27bafa17a504a3095bcb3740933dfa2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c27bafa17a504a3095bcb3740933dfa22021-12-02T03:41:33ZCan a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?1176-63281178-2021https://doaj.org/article/c27bafa17a504a3095bcb3740933dfa22012-10-01T00:00:00Zhttp://www.dovepress.com/can-a-physician-predict-the-clinical-response-to-first-line-immunomodu-a11330https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Zsolt Mezei,1 Daniel Bereczki,1,2 Lilla Racz,1 Laszlo Csiba,1 Tunde Csepany11Department of Neurology, University of Debrecen, Debrecen, Hungary; 2Department of Neurology, Semmelweis University, Budapest, HungaryBackground: Decreased relapse rate and slower disease progression have been reported with long-term use of immunomodulatory treatments (IMTs, interferon beta or glatiramer acetate) in relapsing–remitting multiple sclerosis. There are, however, patients who do not respond to such treatments, and they can be potential candidates for alternative therapeutic approaches.Objective: To identify clinical factors as possible predictors of poor long-term response.Methods: A 9-year prospective, continuous follow-up at a single center in Hungary to assess clinical efficacy of IMT.Results: In a patient group of 81 subjects with mean IMT duration of 54 ± 33 months, treatment efficacy expressed as annual relapse rate and change in clinical severity from baseline did not depend on the specific IMT (any of the interferon betas or glatiramer acetate), and on mono- or multifocal features of the initial appearance of the disease. Responders had shorter disease duration and milder clinical signs at the initiation of treatment. Relapse-rate reduction in the initial 2 years of treatment predicted clinical efficacy in subsequent years.Conclusion: Based on these observations, we suggest that a 2-year trial period is sufficient to decide on the efficacy of a specific IMT. For those with insufficient relapse reduction in the first 2 years of treatment, a different IMT or other therapeutic approaches should be recommended.Keywords: multiple sclerosis, immunomodulatory, EDSS, relapse, responseMezei ZBereczki DRacz LCsiba LCsepany TDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 465-473 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Mezei Z Bereczki D Racz L Csiba L Csepany T Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis? |
| description |
Zsolt Mezei,1 Daniel Bereczki,1,2 Lilla Racz,1 Laszlo Csiba,1 Tunde Csepany11Department of Neurology, University of Debrecen, Debrecen, Hungary; 2Department of Neurology, Semmelweis University, Budapest, HungaryBackground: Decreased relapse rate and slower disease progression have been reported with long-term use of immunomodulatory treatments (IMTs, interferon beta or glatiramer acetate) in relapsing–remitting multiple sclerosis. There are, however, patients who do not respond to such treatments, and they can be potential candidates for alternative therapeutic approaches.Objective: To identify clinical factors as possible predictors of poor long-term response.Methods: A 9-year prospective, continuous follow-up at a single center in Hungary to assess clinical efficacy of IMT.Results: In a patient group of 81 subjects with mean IMT duration of 54 ± 33 months, treatment efficacy expressed as annual relapse rate and change in clinical severity from baseline did not depend on the specific IMT (any of the interferon betas or glatiramer acetate), and on mono- or multifocal features of the initial appearance of the disease. Responders had shorter disease duration and milder clinical signs at the initiation of treatment. Relapse-rate reduction in the initial 2 years of treatment predicted clinical efficacy in subsequent years.Conclusion: Based on these observations, we suggest that a 2-year trial period is sufficient to decide on the efficacy of a specific IMT. For those with insufficient relapse reduction in the first 2 years of treatment, a different IMT or other therapeutic approaches should be recommended.Keywords: multiple sclerosis, immunomodulatory, EDSS, relapse, response |
| format |
article |
| author |
Mezei Z Bereczki D Racz L Csiba L Csepany T |
| author_facet |
Mezei Z Bereczki D Racz L Csiba L Csepany T |
| author_sort |
Mezei Z |
| title |
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis? |
| title_short |
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis? |
| title_full |
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis? |
| title_fullStr |
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis? |
| title_full_unstemmed |
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis? |
| title_sort |
can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis? |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/c27bafa17a504a3095bcb3740933dfa2 |
| work_keys_str_mv |
AT mezeiz canaphysicianpredicttheclinicalresponsetofirstlineimmunomodulatorytreatmentinrelapsingampndashremittingmultiplesclerosis AT bereczkid canaphysicianpredicttheclinicalresponsetofirstlineimmunomodulatorytreatmentinrelapsingampndashremittingmultiplesclerosis AT raczl canaphysicianpredicttheclinicalresponsetofirstlineimmunomodulatorytreatmentinrelapsingampndashremittingmultiplesclerosis AT csibal canaphysicianpredicttheclinicalresponsetofirstlineimmunomodulatorytreatmentinrelapsingampndashremittingmultiplesclerosis AT csepanyt canaphysicianpredicttheclinicalresponsetofirstlineimmunomodulatorytreatmentinrelapsingampndashremittingmultiplesclerosis |
| _version_ |
1718401696375242752 |